Episode Details
Back to Episodes
1.63 POLO, TITAN, & from ASCO: FDA Approval, Surrogate Endpoints, and Patient Experience
Published 7 years, 3 months ago
Description
This week we cover some of the highlights from this year's ASCO annual meeting. We discuss the POLO study "Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer" and the TITAN study "Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer", both recently published in NEJM. We end with a presentation titled "Expedited Program Use and Patient Experience in Trials", which was given in a shortened version at ASCO.
POLO: doi.org/10.1056/NEJMoa1903387
TITAN: doi.org/10.1056/NEJMoa1903307
Back us on Patreon! www.patreon.com/plenarysession